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Overview of   Sepsis and Septic Shock
Infection is a pathological process caused by the invasion of  nor-
mally sterile tissue or fluid or body cavity by pathogenic or po-
tentially pathogenic microorganisms. The systemic inflammatory 
response syndrome concept is valid to the extent that a systemic 
inflammatory response can be triggered by a variety of  infectious 
and noninfectious conditions. Signs of  systemic inflammation can 
occur in the absence of  infection among patients with burns, pan-
creatitis, and other disease states. Sepsis is a syndrome character-
ised by a systemic inflammatory response to infection that leads 
to acute organ failure and potentially rapid decline to death. Septic 
shock, the most severe complication of  sepsis, accounts for ap-
proximately 10% of  all admissions to intensive care unit (ICU). 
Septic shock in adults refers to a state of  acute circulatory failure 
characterized by persistent arterial hypotension unexplained by 
other causes. Hypotension is defined by a systolic arterial pres-
sure below 90 mmHg (or, in children, <2 standard devation below 
normal for their age), a mean arterial pressure <60, or a reduction 
in systolic blood pressure of  >40 mmHg from baseline, despite 
adequate volume resuscitation, in the absence of  other causes for 
hypotension [reviewed in [1,2]. 
Sepsis and septic shock are viewed as a complex chain of  systemic 
events in response to invading pathogens involving inflammatory 
and antiinflammatory processes, humoral and cellular reactions, 
respiratory, gastrointestinal, renal, and circulatory dysfunctions 
leading to organ dysfunction and finally to multiple organ dys-
function syndrome and death. The pathogenesis of  sepsis and 
septic shock has long been investigated and, although it is still 
not fully understood, seems to be due to circulating substances 
released by pathogens (e.g., endotoxins) and host immuno-in-
flammatory responses (e.g., cytokines, reactive oxygen and nitro-
gen species, and eicosanoids). Despite intensive basic research 
worldwide and numerous clinical trials, sepsis and septic shock 
remain the most important causes of  morbidity and mortality in 
patients admitted to the ICU. Patients with septic shock present 
typically in their sixth or seventh decade of  life, and the average 
age of  these patients has been reported to continue to increase 
constantly. Predisposing factors include male sex, nonwhite eth-
nic origin in North Americans, comorbid diseases, malignancy, 
immunodeficiency or immunocompromised state, chronic organ 
failure, alcohol dependence, and genetic factors. Patients with dia-
betes mellitus, malignancy, human immunodeficiency virus (HIV) 
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infection, or disrupted skin, especially trauma victims, or surgical 
patients, are more likely to develop severe sepsis. In the United 
States, the number of  cases of  severe sepsis and septic shock has 
been estimated to reach 934,000 and 1,110,000 cases by the years 
2010 and 2020. Severe sepsis and septic shock also consume con-
siderable health care resources with the average cost per case. The 
average costs per case are reported to be $22,100, with annual 
total costs of  $16.7 billion nationally. These annual costs will most 
likely increase in the upcoming years because of  the overall aging 
population, emergence of  newer antimicrobial-resistant bacteria, 
and increasing use of  invasive therapeutic measures [reviewed in 
[1]]. 
The pathopysiological events in sepsis and septic shock are inti-
tiated by entry of  an invasive Gram-negative or Gram-positive 
bacteria into the circulation through the gut, lung, skin, or geni-
tourinary tract during the course of  an infection trigers patho-
physiological events of  sepsis. In addition, the number of  cases 
of  severe sepsis or septic shock due to fungal infections has sig-
nificantly increased. It has been reported that multidrug-resistant 
bacteria and fungi account for 25% of  cases of  severe sepsis and 
septic shock. Viruses and parasites are also isolated in 2% to 4% 
of  cases. On the other hand, a causative organism is not identified 
in 20% to 30% of  cases, because of  the relatively low sensitivity 
of  blood cultures or use of  antibiotics. In 25% of  individuals who 
have severe sepsis or septic shock, multiple sites of  infection can 
account for the clinical presentation. Twenty percent of  individu-
als have severe sepsis or septic shock with infection site unknown 
[reviewed in [1]]. 
Since sepsis and septic shock are the result of  complex interac-
tions between the infecting microorganism and host immune, in-
flammatory, and coagulation responses, the management of  the 
life-threatening conditions is a complex and dynamic process. In 
general, treatment of  sepsis and septic shock is focused on sup-
porting failing organ systems with interventions including (1) im-
proving supportive care (e.g., oxygenation/ventilation strategies, 
optimize fluid/vasopressor use, and early goal-directed therapy), 
(2) antimicrobial therapy, (3) targetting bacterial virulence factors 
(e.g., antiendotoxin antibodies and endotoxin removal columns), 
and (4) targetting host response factors (e.g., corticosteroids, an-
ticytokine drugs, and anticoagulants) [reviewed in [1,2]]. The Sur-
viving Sepsis Campaign, a collaboration of  the Society of  Critical 
Care Medicine, the European Society of  Intensive Care Medicine, 
and the International Sepsis Forum, whose recommendations on 
the management of  sepsis are considered widely, will publish an 
updated version of  the International Guidelines for Management 
of  Severe Sepsis and Septic Shock originally published in 2004 
and last updated in 2008 [3] [for the most recent recommenda-
tions and guidelines from the Surviving Sepsis Campaign, visit 
www.survivingsepsis.org]. These recommendations are intended 
to provide guidance for the clinician caring of  a patient with se-
vere sepsis and septic shock. However, it should be noted that 
recommendations from these guidelines cannot replace the deci-
sion-making capability of  the clinicians when they are provided 
with a patient's unique set of  clinical variables. 
Clinical Characteristics and Outcomes of  Cancer 
Patients with Sepsis and Septic Shock
In particular, septic shock remains a frequent and feared com-
plication in patients with malignancies because of  the underly-
ing immunosupression related to the disease itself  or imposed 
by treatments, including combined regimens of  chemotherapy 
and radiotherapy, high dose steroids, and hematopoietic stem cell 
transplantation [4-6]. 
In comparison to general patients with sepsis or septic shock, 
cancer patients experience prolonged lenghts of  stay and high-
er morbidity and mortality [7,8]. In a recent prospective cohort 
study, Rosolem et al. [9] evaluated the characteristics and out-
comes of  patients with severe sepsis/septic shock (91%) associ-
ated with solid tumor (77%) or hematologic malignancies (23%) 
over a 55-month period. They demonstrated that the most fre-
quent sites of  infection were the lung, abdomen, and urinary tract, 
Gram-negative bacteria were responsible for more than half  of  
the episodes of  infection, and 38% of  patients had polymicro-
bial infections. In addition, ICU, hospital, and 6-month mortality 
rates were 51%, 65%, and 72%, respectively. They also observed 
that organ dysfunctions were asssociated with increased mortality. 
Therefore, the findings of  this study confirm that sepsis remains 
a frequent complication in patients with cancer and associated 
with high mortality. 
Although sepsis and septic shock in patients with cancer remain 
associated with high morbidity, mortality, costs, and use of  ICU 
resources, the outcomes in these patients including those present-
ing with severe infectious complications seem to be improving. 
Indeed, Pene et al. [10] performed a retrospective observational 
study to assess temporal trends in the ICU management and out-
come of  cancer patients (solid tumors or hematologic malignan-
cies) with septic shock between 1998 and 2005. The authors dem-
onstrated that short-term survival rates were significantly higher 
in cancer patients with septic shock admitted to the ICU dur-
ing 2002-2005 compared with the previous 4-year period (1998-
2001). They attributed the increases in survival to both a better 
selection of  patients and improvements in the care and manage-
ment, including new therapeutic strategies for sepsis. In another 
retrospective study, Larche et al. [11] evaluated critically ill cancer 
patients admitted to ICU for septic shock and looked for determi-
nants of  30-day mortality, with a particular attention to outcome 
changes over a 6-year period (1995-2000). The authors demon-
strated that earlier ICU admission and antibiotic treatment of  
critically ill cancer patients with septic shock was associated with 
higher 30-day survival. In a prospective observational study, Tac-
cone et al.[12]reported that patients with cancer were more often 
admitted to the ICU for sepsis and respiratory complications than 
other ICU patients and the outcome of  patients with solid can-
cer was similar to that of  ICU patients without cancer, whereas 
patients with hematological cancer had a worse outcome. In an-
other prospective observational cohort study, Namendys-Silva et 
al. [13] reported that survival in cancer patients having solid tu-
mors (68.3%) and hematological malignancies (31.7%) with septic 
shock admitted to the ICU increased over the 2008-2010 study 
period. They also demonstrated that the most frequent sites of  
infection were abdominal (57.3%) and respiratory (35.8%), the 
most common source of  infection were abdominal with predomi-
nance Gram-negative bacilli (50%), and more than half  of  the pa-
tients (63.4%) had three or more organ dysfunctions (frequently 
for the respiratory, cardiovascular, coagulation, and renal systems) 
on the day of  their admission to the ICU. In a recent retrospec-
tive cohort study, Zuber et al. [[14] evaluated the characteristics 
and outcomes of  septic shock patients with malignancies over a 
12-year period (1997-2008). The authors reported that the ICU 
and hospital mortality rates drammatically dropped over the time 
(from 70.4% and 72.1% in 1997 to 52.5% and 56.1% in 2008, 
respectively). Recently, in a large cohort study, Legrand et al. [15] 
demonstrated that survival increased over the 1998-2008 study 
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period in neutropenic patients having acute leukemia, lymphoma, 
and solid tumors with sepsis or septic shock. They also reported 
that combination antibiotic therapy with an aminoglycoside and 
early catheter removal may improve survival in the patients.    
Biosynthesis and Biologic Effects of  20-Hydrox-
yeicosatetraenoic Acid (20-Hete)
20-HETE is an -hydroxylation product of  arachidonic acid 
(AA) that is produced by cytochrome P450 (CYP) enzymes, 
mainly by the CYP4A and CYP4F isoforms in the kidney, heart, 
liver, brain, lung, and vasculature [1,16-18]. In the vasculature, 20-
HETE causes vasoconstriction in several vascular beds, including 
renal, cerebral, aortic, mesenteric, and coronary arteries [19-23]. 
Activation of  protein kinases, such as mitogen-activated protein 
kinase (MAPK), MAPK kinase (MEK), and extracellular signal-
regulated kinase (ERK) which contribute to the regulation of  
vascular tone, have been shown to mediate the vasoconstrictor 
effect of  20-HETE [24-26]. As opposed to its vasoconstrictor 
effect, 20-HETE has also been reported to produce vasodilation 
in the vasculature including renal and coronary arteries [27-29]. 
These vasodilatory responses of  20-HETE have been attrib-
uted to nitric oxide (NO) release [30], conversion of  20-HETE 
to 20-OH-PGE2 and 20-OH-PGF2 by cyclooxygenase (COX) 
[21,27,31], and increased formation of  PGE2 [32] and PGI2 [27-
29,31]. In addition, 20-HETE has been shown to activate nuclear 
factor-κB (NF-κB) signaling and induce expression of  cellular 
adhesion molecules and cytokines, thereby promoting inflamma-
tion [32,33]. It has also been reported that NO inhibits renal CYP 
-hydroxylase activity and the production of  20-HETE [34,35]. 
Moreover, a NO-induced fall in the endogenous production of  
20-HETE has been found to contribute to the cyclic guanosine 
monophosphate (cGMP)-independent vasodilator effects of  
NO in renal and cerebral microcirculations [34,36]. In addition, 
CYP4A- and CYP4F-derived 20-HETE has been reported to 
be involved in lipopolysaccharide (LPS)-induced acute systemic 
inflammation as a proinflammatory mediator [37,38]. Changes 
in the production of  20-HETE have also been observed in nu-
merous pathological conditions including hypertension, ischemic 
vascular, cerebral, cardiac, and renal diseases, diabetes, inflamma-
tion, polycystic kidney diseases, toxemia of  pregnancy, and cancer 
[1,16-18,39-42].
Role of  20-Hete and Effects of  20-Hete Analogs 
in Sepsis and Septic Shock
Although changes in 20-HETE production have been well stud-
ied in several pathophysiological conditions, little information is 
available concerning the role of  20-HETE in the pathogenesis 
of  inflammatory diseases such as septic shock in humans and 
animals. Recent studies from our laboratory and others provided 
substantial evidence that CYP4A- and CYP4F-derived 20-HETE 
is a one of  the key mediator of  vascular hyporeactivity, hypo-
tension, inflammation, and mortality in rodent models of  septic 
shock induced by LPS.
Our recent studies with the use of  a stable synthetic analog of  
20-HETE,N-[20-hydroxyeicosa-5(Z),14(Z)-dienoyl]glycine, 
5,14-HEDGE, which mimics the effects of  endogenously pro-
duced 20-HETE, (30 mg/kg, s.c., 1 h after LPS injection), and a 
competitive antagonist of  vasoconstrictor effects of  20-HETE, 
20-hydroxyeicosa-6(Z),15(Z)-dienoic acid, 20-HEDE (also 
known as WIT002), (30 mg/kg, s.c., 1 h after LPS injection) sug-
gest that CYP4A-derived 20-HETE is a one of  the key mediator 
of  LPS (Escherichia coli LPS; 10 mg/kg, i.p.)-induced changes 
in the renal and cardiovascular systems in rats and mortality in 
mice [43-46]. Moreover, our data also demonstrate that increased 
expression of  CYP4A1 and CYP2C23 and formation of  vaso-
constrictor eicosanoids (i.e., 20-HETE) and antiinflammatory 
mediators (i.e., epoxyeicosatrienoic acids; EETs) associated with 
suppression of  MEK1/ERK1/2/IB kinase (IKK) /inhibitor 
of  B (IB)-/NF-B and inducible NO synthase (iNOS)/
soluble guanylyl cyclase (GC)/protein kinase G (PKG) pathways, 
COX-2, gp91phox (also known as NOX2), and soluble epoxide 
hydrolase (sEH) as well as production of  NO and vasodilator 
prostanoids (i.e., PGI2 and PGE2), peroxynitrite, and proinflam-
matory cytokines (i.e., tumor necrosis factor [TNF]- and inter-
leukin [IL-8]) participate in the protective effect of  5,14-HEDGE 
against vascular hyporeactivity, hypotension, tachycardia, inflam-
mation, and mortality in the rodent models of  septic shock. In the 
light of  the important role of  20-HETE in the regulation of  renal 
and cardiovascular hemostasis as well as inflammatory process, 
our findings strongly suggest that further studies with stable 20-
HETE mimetics in animal models of  endotoxemia could provide 
a novel approach to treat hypotension, tachycardia, inflammation, 
and mortality which lead to multiple organ failure and death in 
patients with septic shock.
In contrast to our findings, Anwar-Mohamed et al. [37] dem-
onstrated that CYP4A1 mRNA expression was increased in the 
heart of  inflamed animals at 6, 12, and 24 h by 400%, 900%, and 
6000%, respectively, after injection of  LPS (E. coli LPS, O127:B8, 
1 mg/kg, i.p.) to Sprague-Dawley rats. Similarly, but with a lower 
magnitude, renal mRNA expression of  CYP4A1 was increased 
only at 24 h by 100% after injection of  LPS (E. coli LPS, O127:B8, 
1 mg/kg, i.p.) to rats. The LPS-induced changes in the expression 
of  CYP4A1 as well as enhanced expression of  TNF-α and IL-6 
genes in cardiac and renal tissues were also associated with in-
creased production of  20-HETE in the heart microsomes of  in-
flamed animals by 40% ex vivo. The authors suggested that acute 
inflammation causes alteration in cardiac CYP-mediated AA me-
tabolism in favor of  20-HETE formation. However, Theken et 
al. [38] reported that 20-HETE formation in the kidney, but not 
in the heart, decreased 6 or 24 h after injection of  LPS (E. coli 
LPS, O111:B4, 1 mg/kg, i.p.) to C57BL/6 mice leading to the 
conclusion that acute activation of  the innate immune response 
alters CYP expression and eicosanoid metabolism in an isoform-, 
tissue-, and time-dependent manner. Thus, the contradiction be-
tween previously published studies and our results could be at-
tributed to differences in type and strain of  animals, dose regi-
men, strain of  LPS, and time points for measurement of  enzyme 
expression and activity which might reflect the differences in the 
response to LPS treatment.
Role of  20-Hete and Effects of  20-Hete Analogs 
in Cancer
In recent years, increasing evidence has implicated that the 20-
HETE producing CYP4A/4F enzymes also play an important 
role in the regulation of  neovascularization process, including 
vasculogenesis and angiogenesis, that can support tumor progres-
sion. 
In 1997, Goodman et al. [47] reported that CYP arachidonic acid 
epoxygenase and -hydroxylase activities were markedly reduced 
in the tumor tissues, whereas, in the juxtatumor tissue, CYP 
-hydroxylase activity was significantly increased. In this study, 
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mRNA levels for -hydroxylase transcripts were significantly de-
creased in the adenocarcinoma compared with juxtatumor. The 
decrease in CYP4A2 mRNA levels correlated with a decrease in 
the arachidonic acid -hydroxylation metabolite, 20-HETE. The 
production of  20-HETE was significantly higher in juxtatumor 
in agreement with -hydroxylase mRNA. The authors concluded 
that increased generation of  mitogenic activities by -hydroxylase 
and 20-HETE in the juxtatumor may be a contributing factor in 
the development and growth of  neoplastic tissues. 
Chen et al. [48] examined the effects of  inhibiting the formation 
of  20-HETE with N-hydroxy-N-(4-butyl-2-methylphenyl)-
formamidine (HET0016), a selective inhibitor of  CYP4A and 
thus 20-HETE synthesis, on the mitogenic response of  vascular 
endothelial growth factor (VEGF) in human umbilical vein en-
dothelial cells (HUVECs) in vitro, and on growth factor-induced 
angiogenesis in the cornea of  rats in vivo. In this study, HET0016 
abolished the mitogenic response to VEGF in HUVECs and the 
angiogenic response to VEGF, basic fibroblast growth factor 
(BFGF), and epidermal growth factor (EGF) in vivo by 80 to 
90%. Dibromododecenyl methylsulfonimide (DDMS), a structur-
ally and mechanistically different inhibitor of  20-HETE synthe-
sis, also abolished angiogenic responses when tested with VEGF. 
In addition, administration of  the stable 20-HETE agonist, 
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid (WIT003) induced mi-
togenesis in HUVECs and angiogenesis in the rat cornea in vivo. 
When administered locally into the cornea, HET0016 reduced the 
angiogenic response to human glioblastoma cancer cells (U251) 
by 70%. The authors concluded that a product of  CYP4A prod-
uct, possibly 20-HETE, plays a critical role in the regulation of  
angiogenesis and may provide a useful target for reduction of  
pathological angiogenesis. 
In a parallel study, Guo et al. [49] reported that HET0016 inhib-
its U251 cell proliferation in a dose-dependent manner. In this 
study, HET0016 also suppressed 56% of  U251 proliferation and 
significantly increased the proportions of  the cells arrested in the 
G0/G1 phase of  the cell cycle. Exposure to HET0016 reduced 
protein tyrosine and ERK1/2 phosphorylation. Furthermore, 
HET0016 significantly inhibited the U251 proliferation and phos-
phorylation of  both the EGF receptor and ERK1/2 induced by 
EGF. These authors concluded that HET0016 may be the pro-
totype of  compounds with antitumor activity in glioma since it 
prevented U251 proliferation by inhibiting 20-HETE synthesis. 
Subsequently, the authors demonstrated that HET0016 reduced 
the proliferation of  9L rat gliosarcoma cells in vitro by 55% after 
48 h of  incubation, and this was associated with a fall in ERK1/2 
and stress-activatedprotein kinase/c-Jun NH2-terminal kinase 
phosphorylation and increased apoptosis [50]. In this study, 
HET0016 inhibited EGF and platelet-derived growth factor 
(PDGF)-induced proliferation and diminished phosphorylation 
of  PDGF receptors. The 20-HETE analog, WIT003, increased 
9L cell proliferation. In vivo, chronic administration of  HET0016 
(10 mg/kg/day i.p.) for 2 weeks reduced the volume of  9L tu-
mors by 80%. This was accompanied by a 4-fold reduction in 
the mitotic index, a 3- to 4-fold increase in the apoptotic index, 
and a 50% decrease in vascularization in the tumor. HET0016 
treatment increased mean survival time of  the animals from 17 to 
22 days. Liquid chromatography/mass spectrometry experiments 
indicated that neither 9L cells grown in vitro nor 9L tumors re-
moved produce 20-HETE when incubated with arachidonic acid. 
The normal surrounding brain tissue, however, avidly makes 20-
HETE, and this activity is selectively inhibited by HET0016. The 
authors suggested that HET0016 may be the prototype of  a class 
of  antigrowth compounds that may be efficacious for treating 
malignant brain tumors. They also concluded that HET0016 may 
act in part by inhibiting the formation of  20-HETE by the sur-
rounding tissue in vivo, however, its antiproliferative effects on 
9L cells in vitro seem unrelated to its ability to inhibit the forma-
tion of  20-HETE. The same group also showed U251 cells trans-
fected with CYP4A1 cDNA (U251 O) increased the formation 
of  20-HETE from less than 1 to over 60 pmol/min/mg proteins 
and increased their proliferation rate by 2-fold [51]. In this study, 
compared with control U251, U251 O cells were rounded, small-
er, showed a disorganized cytoskeleton, exhibited reduced vincu-
lin staining, and were easily detached from the growing surface. 
There was a marked increase in dihydroethidium staining, sug-
gesting increased oxidative stress. The expression of  phosphoryl-
ated ERK1/2, cyclin D1/2, and VEGF was markedly elevated 
in U251 O. The hyperproliferative and signaling effects seen in 
U251 O cells are abolished by selective inhibition of  CYP4A and 
20-HETE formation with HET0016, by small interfering RNA 
against the enzyme, and by the 20-HETE antagonist, 20-HEDE. 
In vivo, implantation of  U251O cells in the brain of  nude rats 
resulted in a 10-fold larger tumor volume (10 days postimplan-
tation) compared with animals receiving mock-transfected U251 
cells. The authors concluded that elevations in CYP4A-induced 
20-HETE synthesis in a human glioma U251 cell line lead to an 
increased growth both in vitro and in vivo, suggesting that 20-
HETE may have proto-oncogenic properties in U251 human 
gliomas. 
Recently, Alexanian et al. [52] examined the ability of  inhibitors 
of  the synthesis or actions of  20-HETE to inhibit proliferation 
of  human renal carcinoma cell lines. In this study, addition of  
HET0016 and the 20-HETE antagonist, 20-HEDE, inhibited 
the proliferation of  786-O and 769-P human renal cell carcinoma 
lines. HET0016 and 20-HEDE had little effect on the prolif-
eration of  primary cultures of  normal human proximal tubule 
epithelial cells. 20-HEDE (10 mg/kg, s.c.) administered daily to 
athymic nude mice implanted subcutaneously with 786-O cells 
reduced the growth of  the tumors by 84% compared to vehicle. 
The authors concluded that 20-HETE is required for prolifera-
tion of  human renal epithelial cancers. More recently, the same 
group reported that the expression of  CYP4A/4F genes is mark-
edly elevated in thyroid, breast, colon, and ovarian cancer samples 
in comparison to matched normal tissues [53]. In this study, the 
levels of  the CYP4F2 protein and of  20-HETE were also higher 
in ovarian cancer samples compared to normal control tissues. A 
stable 20-HETE agonist induced activation of  the small-GTPase 
Ras in human proximal tubule epithelial cells cells. The authors 
concluded that the finding of  elevated expression of  CYP4A/F 
enzymes in human cancer tissue suggests that 20-HETE inhibi-
tors and antagonists may be useful in the treatment of  human 
cancer. 
Yu et al. [54] examined the role of  CYP -hydroxylase in an-
giogenesis and metastasis of  human non-small cell lung cancer 
(NSCLC). In this study, addition of  WIT003 or overexpression 
of  CYP4A11 with an associated increase in 20-HETE produc-
tion signifcantly induced invasion and expression of  VEGF and 
matrix metalloproteinase (MMP)-9. Treatment of  A549 cells 
with HET0016 or 20-HEDE inhibited invasion with reduction 
in VEGF and MMP-9. The phosphoinositide-3-kinase (PI3K) or 
ERK inhibitors also attenuated expression of  VEGF and MMP-
9. Compared with control, CYP4A11 transfection signifcantly 
increased tumor weight, microvessel density (MVD), and lung 
metastasis by 2.5-fold, 2-fold, and 3-fold, respectively. In con-
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trast, 20-HEDE or HET0016 decreased tumor volume, MVD, 
and spontaneous pulmonary metastasis occurrences. The authors 
concluded that CYP-hydroxylase promotes tumor angiogenesis 
and metastasis by upregulation of  VEGF and MMP-9 via PI3K 
and ERK1/2 signaling in human NSCLC cells. More recently, the 
same group demonstrated that stable expression of  CYP4Z1 a 
novel CYP4 family member, which is over-expressed in human 
mammary carcinoma and associated with high-grade tumors and 
poor prognosis, in T47D and BT-474 human breast cancer cells 
significantly increased mRNA expression and production of  
VEGF-A, and decreased mRNA levels and secretion of  tissue 
inhibitor of  metalloproteinase-2 (TIMP-2), without affecting cell 
proliferation and anchorage-independent cell growth in vitro [55]. 
In this study, the conditioned medium from CYP4Z1-expressing 
cells also enhanced proliferation, migration and tube formation 
of  HUVECs, and promoted angiogenesis in the zebrafish em-
bryo and chorioallantoic membrane of  the chick embryo. In ad-
dition, there were lower levels of  myristic acid and lauric acid, 
and higher contents of  20-HETE in CYP4Z1-expressing T47D 
cells compared with vector control. CYP4Z1 overexpression sig-
nificantly increased tumor weight and microvessel density by 2.6-
fold and 1.9-fold in human tumor xenograft models, respectively. 
Moreover, CYP4Z1 transfection increased the phosphorylation 
of  ERK1/2 and PI3K/Akt, while PI3K or ERK inhibitors and 
siRNA silencing reversed CYP4Z1-mediated changes in VEGF-
A and TIMP-2 expression. Conversely, HET0016 potently inhib-
ited the tumor-induced angiogenesis with associated changes in 
the intracellular levels of  myristic acid, lauric acid and 20-HETE. 
The authors suggested that increased CYP4Z1 expression pro-
motes tumor angiogenesis and growth in breast cancer partly via 
PI3K/Akt and ERK1/2 activation.
Although the pro-angiogenic, proto-oncogenic, and mitogenic ef-
fects of  20-HETE have extensively been investigated in human 
carcinoma tissues and cell lines both in vitro and in vivo, little 
is known about the role of  20-HETE in cancer patients. In one 
study, Nithipatikom et al. [56] investigated the relationship be-
tween the concentrations of  urinary free acids of  12-HETE and 
20-HETE) and the benign prostatic hypertrophy (BPH) and pros-
tate cancer. In this study, urinary concentrations of  12-HETE and 
20-HETE of  BPH and prostate cancer patients were significantly 
higher than normal subjects. After removal of  the prostate gland, 
the urinary concentrations of  these eicosanoids decreased to con-
centrations similar to the normal subjects. The authors concluded 
that urinary free acids of  12-HETE and 20-HETE indicate an 
abnormality of  the prostate gland. 
Conclusion
The current management of  cancer patients with sepsis and septic 
shock relies on immediate treatment with antibiotics and strong 
supportive care to control hypotension, tachycardia, cardiac out-
put, and tissue oxygenation to maintain organ function. However, 
the failure of  conventional therapy is that the pathophysiology of  
septic shock is the result of  a highly complex set of  processes in 
which the host response becomes dysregulated and causes cellular 
damage, tissue damage, and, ultimately, organ failure. Accumu-
lating evidence suggest that the importance and contribution of  
20-HETE generated via CPY4A and CYP4F to renal and car-
diovascular diseases associated with inflammation and cancer is 
beginning to emerge. Although inhibitors of  20-HETE synthesis 
such as HT0016 and DDMS as well as its competitive antagonist 
20-HEDE have been proposed to be useful in the treatment of  
cancer, in the light of  the important role of  NO, prostanoids, and 
20-HETE in hypotension, inflammation, MOF, and mortality, the 
interaction of  NOS, COX, and CYP4A/4F pathways should be 
considered when developing new strategies for drug development 
in the treatment of  cancer patients with sepsis and septic shock. 
More importantly, further studies with stable mimetics of  20-
HETE, such as 5,14-HEDGE, in experimental models of  cancer 
in endotoxemic animals could provide a novel approach to treat 
hypotension, inflammation, and mortality which lead to MOF and 
death in cancer patients with septic shock admitted to the ICU.
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